Antiphospholipid inner ear syndrome

Debbie Aviva Mouadeb, Michael J. Ruckenstein

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Objective: This study was initiated to clarify the possible association between antiphospholipid antibodies, mediators of microthrombus formation, and sensorineural hearing loss (SNHL) of unknown origin in a large cohort of patients. Study Design: Prospective study. Methods: The study cohort consists of 168 adult patients (≥18 yr) referred to the University of Pennsylvania's Division of Neurotology and Balance Center for diagnosis and treatment of progressive hearing loss with or without vertigo. A comprehensive screening panel of blood tests for autoimmune and infectious diseases was applied to all patients, including testing for anticardiolipin antibodies, anti-B2 glycoprotein, and lupus anticoagulant. Results: Forty-two patients (25%) had at least one elevated antiphospholipid antibody marker. Twenty patients had two or more positive test results. Of the 42 patients, 64% (n = 27) met the diagnostic criteria for Ménière disease, and the remainder were diagnosed with idiopathic SNHL. Within this group of patients, 24 patients (57%) had unilateral hearing loss, and 18 (44%) had bilateral hearing loss. Conclusions: These data support the hypothesis that antiphospholipid antibodies are involved in the pathogenesis of some forms of inner ear dysfunction, presumably by causing microthrombus formation in the labyrinthine vasculature. Basic science studies are required to better understand the mechanisms by which antiphospholipid antibodies mediate inner ear dysfunction. Clinical studies to evaluate the efficacy of anticoagulation in this group of patients are also required.

Original languageEnglish (US)
Pages (from-to)879-883
Number of pages5
JournalLaryngoscope
Volume115
Issue number5
DOIs
StatePublished - May 1 2005

Fingerprint

Inner Ear
Antiphospholipid Antibodies
Sensorineural Hearing Loss
Neurotology
Unilateral Hearing Loss
Bilateral Hearing Loss
Lupus Coagulation Inhibitor
Anticardiolipin Antibodies
Vertigo
Hematologic Tests
Hearing Loss
Autoimmune Diseases
Communicable Diseases
Glycoproteins
Cohort Studies
Prospective Studies

Keywords

  • Anticardiolipin antibody
  • Antiphospholipid antibody syndrome
  • Audiovestibular dysfunction
  • Sensorineural hearing loss

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Antiphospholipid inner ear syndrome. / Mouadeb, Debbie Aviva; Ruckenstein, Michael J.

In: Laryngoscope, Vol. 115, No. 5, 01.05.2005, p. 879-883.

Research output: Contribution to journalArticle

Mouadeb, Debbie Aviva ; Ruckenstein, Michael J. / Antiphospholipid inner ear syndrome. In: Laryngoscope. 2005 ; Vol. 115, No. 5. pp. 879-883.
@article{f28ba0e8f4a541b090ea411399eaf906,
title = "Antiphospholipid inner ear syndrome",
abstract = "Objective: This study was initiated to clarify the possible association between antiphospholipid antibodies, mediators of microthrombus formation, and sensorineural hearing loss (SNHL) of unknown origin in a large cohort of patients. Study Design: Prospective study. Methods: The study cohort consists of 168 adult patients (≥18 yr) referred to the University of Pennsylvania's Division of Neurotology and Balance Center for diagnosis and treatment of progressive hearing loss with or without vertigo. A comprehensive screening panel of blood tests for autoimmune and infectious diseases was applied to all patients, including testing for anticardiolipin antibodies, anti-B2 glycoprotein, and lupus anticoagulant. Results: Forty-two patients (25{\%}) had at least one elevated antiphospholipid antibody marker. Twenty patients had two or more positive test results. Of the 42 patients, 64{\%} (n = 27) met the diagnostic criteria for M{\'e}ni{\`e}re disease, and the remainder were diagnosed with idiopathic SNHL. Within this group of patients, 24 patients (57{\%}) had unilateral hearing loss, and 18 (44{\%}) had bilateral hearing loss. Conclusions: These data support the hypothesis that antiphospholipid antibodies are involved in the pathogenesis of some forms of inner ear dysfunction, presumably by causing microthrombus formation in the labyrinthine vasculature. Basic science studies are required to better understand the mechanisms by which antiphospholipid antibodies mediate inner ear dysfunction. Clinical studies to evaluate the efficacy of anticoagulation in this group of patients are also required.",
keywords = "Anticardiolipin antibody, Antiphospholipid antibody syndrome, Audiovestibular dysfunction, Sensorineural hearing loss",
author = "Mouadeb, {Debbie Aviva} and Ruckenstein, {Michael J.}",
year = "2005",
month = "5",
day = "1",
doi = "10.1097/01.MLG.0000158666.15447.37",
language = "English (US)",
volume = "115",
pages = "879--883",
journal = "Laryngoscope",
issn = "0023-852X",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Antiphospholipid inner ear syndrome

AU - Mouadeb, Debbie Aviva

AU - Ruckenstein, Michael J.

PY - 2005/5/1

Y1 - 2005/5/1

N2 - Objective: This study was initiated to clarify the possible association between antiphospholipid antibodies, mediators of microthrombus formation, and sensorineural hearing loss (SNHL) of unknown origin in a large cohort of patients. Study Design: Prospective study. Methods: The study cohort consists of 168 adult patients (≥18 yr) referred to the University of Pennsylvania's Division of Neurotology and Balance Center for diagnosis and treatment of progressive hearing loss with or without vertigo. A comprehensive screening panel of blood tests for autoimmune and infectious diseases was applied to all patients, including testing for anticardiolipin antibodies, anti-B2 glycoprotein, and lupus anticoagulant. Results: Forty-two patients (25%) had at least one elevated antiphospholipid antibody marker. Twenty patients had two or more positive test results. Of the 42 patients, 64% (n = 27) met the diagnostic criteria for Ménière disease, and the remainder were diagnosed with idiopathic SNHL. Within this group of patients, 24 patients (57%) had unilateral hearing loss, and 18 (44%) had bilateral hearing loss. Conclusions: These data support the hypothesis that antiphospholipid antibodies are involved in the pathogenesis of some forms of inner ear dysfunction, presumably by causing microthrombus formation in the labyrinthine vasculature. Basic science studies are required to better understand the mechanisms by which antiphospholipid antibodies mediate inner ear dysfunction. Clinical studies to evaluate the efficacy of anticoagulation in this group of patients are also required.

AB - Objective: This study was initiated to clarify the possible association between antiphospholipid antibodies, mediators of microthrombus formation, and sensorineural hearing loss (SNHL) of unknown origin in a large cohort of patients. Study Design: Prospective study. Methods: The study cohort consists of 168 adult patients (≥18 yr) referred to the University of Pennsylvania's Division of Neurotology and Balance Center for diagnosis and treatment of progressive hearing loss with or without vertigo. A comprehensive screening panel of blood tests for autoimmune and infectious diseases was applied to all patients, including testing for anticardiolipin antibodies, anti-B2 glycoprotein, and lupus anticoagulant. Results: Forty-two patients (25%) had at least one elevated antiphospholipid antibody marker. Twenty patients had two or more positive test results. Of the 42 patients, 64% (n = 27) met the diagnostic criteria for Ménière disease, and the remainder were diagnosed with idiopathic SNHL. Within this group of patients, 24 patients (57%) had unilateral hearing loss, and 18 (44%) had bilateral hearing loss. Conclusions: These data support the hypothesis that antiphospholipid antibodies are involved in the pathogenesis of some forms of inner ear dysfunction, presumably by causing microthrombus formation in the labyrinthine vasculature. Basic science studies are required to better understand the mechanisms by which antiphospholipid antibodies mediate inner ear dysfunction. Clinical studies to evaluate the efficacy of anticoagulation in this group of patients are also required.

KW - Anticardiolipin antibody

KW - Antiphospholipid antibody syndrome

KW - Audiovestibular dysfunction

KW - Sensorineural hearing loss

UR - http://www.scopus.com/inward/record.url?scp=18044371028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18044371028&partnerID=8YFLogxK

U2 - 10.1097/01.MLG.0000158666.15447.37

DO - 10.1097/01.MLG.0000158666.15447.37

M3 - Article

C2 - 15867658

AN - SCOPUS:18044371028

VL - 115

SP - 879

EP - 883

JO - Laryngoscope

JF - Laryngoscope

SN - 0023-852X

IS - 5

ER -